Have a personal or library account? Click to login
AXL inhibitors selected by molecular docking: Option for reducing SARS-CoV-2 entry into cells Cover

AXL inhibitors selected by molecular docking: Option for reducing SARS-CoV-2 entry into cells

Acta Pharmaceutica
Volume 72 (2022): Issue 3 (September 2022)
By: Octavio Galindo-Hernández and  José Luis Vique-Sánchez  
Open Access
|Apr 2022

Authors

Octavio Galindo-Hernández

Facultad de Medicina Mexicali, Universidad Autónoma de Baja, California

José Luis Vique-Sánchez

jvique@uabc.edu.mx

Facultad de Medicina Mexicali, Universidad Autónoma de Baja, California
DOI: https://doi.org/10.2478/acph-2022-0024 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 329 - 343
Accepted on: Oct 18, 2021
|
Published on: Apr 13, 2022
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
COVID-19,
SARS-CoV-2,
AXL ligand,
molecular docking,
NTD-S1,
S protein
Related subjects:
Pharmacy,
Pharmacy, other

© 2022 Octavio Galindo-Hernández, José Luis Vique-Sánchez, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 72 (2022): Issue 3 (September 2022)Next article